Healthcare / BiotechnologyNasdaqCM
$1.63
-0.03 (-1.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-33.3M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$98M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-76.5%
↓Gross Margin
N/A
•Debt/Equity
0.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-33.8M · FCF $-33.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Net Income | $-33.8M | $-33.8M | $-55.9M | $-37.5M | $-62.0M | $-57.8M | $-37.6M | $-60.8M | $-38.9M | $-22.3M | $-18.7M | $-12.1M | $-5.2M | $13.1M |
| EBITDA | $-31.7M | $-31.7M | $-53.7M | $-35.2M | $-60.1M | — | — | — | — | — | — | — | — | — |
| EPS | -0.56 | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 | — | — | — | — | — | -1.40 | -3.09 | -17.61 |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.35 | 0.35 | 0.22 | 0.13 | 0.11 | 0.08 | 0.19 | 0.30 | — | 0.03 | 0.06 | 0.05 | 0.19 | -0.03 |
| Current Ratio | 2.72 | 2.72 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-33.3M | $-33.3M | $-43.2M | $-30.3M | $-56.7M | $-42.6M | — | $-45.0M | $-30.1M | $-19.2M | — | — | — | — |
| Returns | ||||||||||||||
| ROE | -76.5% | -76.5% | -78.7% | -31.3% | -41.1% | -28.1% | -63.1% | -126.5% | -44.9% | -56.4% | -86.4% | -48.6% | -82.5% | -32.5% |
| Valuation | ||||||||||||||
| P/B | 2.21 | 2.21 | 4.57 | 1.59 | 2.70 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| EPS Growth | 40.4% | 40.4% | -46.9% | 39.6% | — | — | — | — | — | — | — | 54.7% | 82.5% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.94 → -0.56
Residual
-23.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.